115 related articles for article (PubMed ID: 15773344)
1. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y; Ariga T; Ohtsu M
Nihon Rinsho; 2005 Mar; 63(3):448-52. PubMed ID: 15773344
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy for adenosine deaminase deficiency].
Sakiyama Y
Hokkaido Igaku Zasshi; 1996 Jan; 71(1):27-32. PubMed ID: 8727372
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow gene therapy for adenosine deaminase deficiency.
Kaptein LC; Einerhand MP; Braakman E; Valerio D; van Beusechem VW
Immunodeficiency; 1993; 4(1-4):335-45. PubMed ID: 7909479
[TBL] [Abstract][Full Text] [Related]
4. In vivo kinetics of transduced cells in peripheral T cell-directed gene therapy: role of CD8+ cells in improved immunological function in an adenosine deaminase (ADA)-SCID patient.
Kawamura N; Ariga T; Ohtsu M; Kobayashi I; Yamada M; Tame A; Furuta H; Okano M; Egashira M; Niikawa N; Kobayashi K; Sakiyama Y
J Immunol; 1999 Aug; 163(4):2256-61. PubMed ID: 10438969
[TBL] [Abstract][Full Text] [Related]
5. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.
Gaspar HB; Bjorkegren E; Parsley K; Gilmour KC; King D; Sinclair J; Zhang F; Giannakopoulos A; Adams S; Fairbanks LD; Gaspar J; Henderson L; Xu-Bayford JH; Davies EG; Veys PA; Kinnon C; Thrasher AJ
Mol Ther; 2006 Oct; 14(4):505-13. PubMed ID: 16905365
[TBL] [Abstract][Full Text] [Related]
6. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield MS
Semin Hematol; 1998 Oct; 35(4):291-8. PubMed ID: 9801258
[TBL] [Abstract][Full Text] [Related]
7. [Study of T cell-directed gene transfer for a patient with ADA deficiency].
Sakiyama Y; Ariga T; Kawamura N
Nihon Rinsho; 1998 Mar; 56(3):696-700. PubMed ID: 9549359
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992.
Blaese RM; Culver KW; Chang L; Anderson WF; Mullen C; Nienhuis A; Carter C; Dunbar C; Leitman S; Berger M
Hum Gene Ther; 1993 Aug; 4(4):521-7. PubMed ID: 7691188
[TBL] [Abstract][Full Text] [Related]
9. [The gene therapy for a patient with ADA deficiency; report of the first gene therapy trial in Japan].
Ariga T; Kawamura N; Sakiyama Y
Nihon Rinsho; 1997 Jun; 55(6):1572-9. PubMed ID: 9200950
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow gene transfer in three patients with adenosine deaminase deficiency.
Hoogerbrugge PM; van Beusechem VW; Fischer A; Debree M; le Deist F; Perignon JL; Morgan G; Gaspar B; Fairbanks LD; Skeoch CH; Moseley A; Harvey M; Levinsky RJ; Valerio D
Gene Ther; 1996 Feb; 3(2):179-83. PubMed ID: 8867866
[TBL] [Abstract][Full Text] [Related]
11. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase.
Chun JD; Lee N; Kobayashi RH; Chaffee S; Hershfield MS; Stiehm ER
Ann Allergy; 1993 Jun; 70(6):462-6. PubMed ID: 8507039
[TBL] [Abstract][Full Text] [Related]
12. Development of gene therapy for immunodeficiency: adenosine deaminase deficiency.
Blaese RM
Pediatr Res; 1993 Jan; 33(1 Suppl):S49-53; discussion S53-5. PubMed ID: 8433875
[TBL] [Abstract][Full Text] [Related]
13. Adenosine deaminase deficiency.
Hirschhorn R
Immunodefic Rev; 1990; 2(3):175-98. PubMed ID: 2078332
[TBL] [Abstract][Full Text] [Related]
14. Visible integration of the adenosine deaminase (ADA) gene into the recipient genome after gene therapy.
Egashira M; Ariga T; Kawamura N; Miyoshi O; Niikawa N; Sakiyama Y
Am J Med Genet; 1998 Jan; 75(3):314-7. PubMed ID: 9475605
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for adenosine deaminase deficiency.
Aiuti A; Ficara F; Cattaneo F; Bordignon C; Roncarolo MG
Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):461-6. PubMed ID: 14612670
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).
Chan B; Wara D; Bastian J; Hershfield MS; Bohnsack J; Azen CG; Parkman R; Weinberg K; Kohn DB
Clin Immunol; 2005 Nov; 117(2):133-43. PubMed ID: 16112907
[TBL] [Abstract][Full Text] [Related]
17. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
[TBL] [Abstract][Full Text] [Related]
18. In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.
Carbonaro DA; Jin X; Petersen D; Wang X; Dorey F; Kil KS; Aldrich M; Blackburn MR; Kellems RE; Kohn DB
Mol Ther; 2006 Jun; 13(6):1110-20. PubMed ID: 16651028
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency.
Rogers MH; Lwin R; Fairbanks L; Gerritsen B; Gaspar HB
J Pediatr; 2001 Jul; 139(1):44-50. PubMed ID: 11445793
[TBL] [Abstract][Full Text] [Related]
20. Genetic correction of cultured T cells from an adenosine deaminase-deficient patient: characteristics of non-transduced and transduced T cells.
Braakman E; Van Beusechem VW; Van Krimpen BA; Fischer A; Bolhuis RL; Valerio D
Eur J Immunol; 1992 Jan; 22(1):63-9. PubMed ID: 1730260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]